A Phase 2 GFR Measuring Study of RTA 402 in CKD Patients With Type 2 Diabetes Mellitus

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221750

Enrollment

Registered

2012-03-28

Start date

2012-03-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD patients with type 2 diabetes

Interventions

investigational material(s) Generic name etc : RTA 402 INN of investigational material : To be determined Therapeutic category code : 219 Other cardiovascular agents Dosage and Administration for Inve

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -CKD patients with type 2 diabetes mellitus -Patients whose eGFR levels are eligible for this study -Patients being treated with stable dose of ACE inhibitors and/or ARB etc.

Exclusion criteria

Exclusion criteria: -Patients with Type 1 diabetes -Patients with known non-diabetic renal disease -Patients with a history of renal transplantation -Patients with mean SBP > 160 mmHg or mean DBP > 90 mmHg -Patients with HbA1C > 10% -Patients with cardiovascular disease specified in the study protocol -Patients for whom Inulead(R) injection is contraindicated etc.

Design outcomes

Primary

Measure	Time frame
Safety and Efficacy Safety: adverse events, Efficacy: glomerular filtration rate	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026